Immunotherapy with Autologous Tregs in T1DM

This study is testing whether infusing a patient's own regulatory immune cells (called Tregs, expanded in the lab) can help preserve the insulin-producing cells remaining in the pancreas and reduce the need for insulin injections in people with Type 1 diabetes. **You may be eligible if...** - You have been diagnosed with Type 1 diabetes per current Chinese guidelines - You are between 8 and 65 years old - You have at least one positive diabetes-related autoantibody and/or limited remaining insulin production - You can provide written consent and comply with study requirements **You may NOT be eligible if...** - You are currently experiencing uncontrolled diabetic ketoacidosis - You have a known or suspected tumor or severe allergies - You have severe heart, liver, kidney, rheumatic, respiratory, nervous system, or infectious disease - Your diabetes is caused by something other than autoimmune destruction (e.g., gestational diabetes, genetic mutation) Talk to your doctor to see if this trial is right for you.